Identification of mitochondria-targeting anticancer compounds by an in vitro strategy

Area of Science:

• Mitochondrial biology
• Apoptosis research
• Drug discovery and development

Background:

• Mitochondria are critical in initiating apoptosis, the programmed cell death pathway.
• Targeting mitochondria with anticancer drugs can overcome resistance to conventional therapies.
• Developing rapid methods to identify such drugs is crucial for cancer treatment advancement.

Purpose of the Study:

• To develop and validate an in vitro strategy for rapid identification of mitochondria-targeting anticancer agents.
• To assess the ability of potential therapeutic compounds to induce apoptosis by directly affecting mitochondria.

Main Methods:

• Isolated mitochondria were treated with various anticancer compounds.
• A laboratory-built high-sensitivity flow cytometer was used to measure side scatter and mitochondrial membrane potential (Δψ(m)) fluorescence.
• The method was validated using eight established anticarcinogens.

Main Results:

• The developed flow cytometry assay successfully identified compounds inducing dose-dependent loss of mitochondrial membrane potential (Δψ(m)).
• Paclitaxel, antimycin A, betulinic acid, curcumin, ABT-737, and triptolide demonstrated Δψ(m) loss, consistent with their known mechanisms.
• Cisplatin and actinomycin D did not induce significant Δψ(m) loss, aligning with their non-mitochondrial targeting pathways.

Conclusions:

• The developed in vitro flow cytometry method is effective for rapidly screening and identifying anticancer compounds that target mitochondria.
• This approach offers a valuable tool for discovering novel mitochondria-directed cancer therapeutics and understanding apoptosis induction mechanisms.